Switch theme
Sign up to access all valuation multiples
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
2017
81
LTM Revenue $6.7M
LTM EBITDA -$117M
$416M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Janux Therapeutics has a last 12-month revenue (LTM) of $6.7M and a last 12-month EBITDA of -$117M.
In the most recent fiscal year, Janux Therapeutics achieved revenue of $10.6M and an EBITDA of -$96.8M.
Janux Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Janux Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $6.7M | XXX | $10.6M | XXX | XXX | XXX |
| Gross Profit | $6.7M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$117M | XXX | -$96.8M | XXX | XXX | XXX |
| EBITDA Margin | -1752% | XXX | -914% | XXX | XXX | XXX |
| EBIT | -$124M | XXX | -$98.8M | XXX | XXX | XXX |
| EBIT Margin | -1856% | XXX | -934% | XXX | XXX | XXX |
| Net Profit | -$91.3M | XXX | -$69.0M | XXX | XXX | XXX |
| Net Margin | -1365% | XXX | -652% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Janux Therapeutics's stock price is $24.
Janux Therapeutics has current market cap of $1.4B, and EV of $416M.
See Janux Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $416M | $1.4B | XXX | XXX | XXX | XXX | $-1.57 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Janux Therapeutics has market cap of $1.4B and EV of $416M.
Janux Therapeutics's trades at 39.3x EV/Revenue multiple, and -4.3x EV/EBITDA.
Equity research analysts estimate Janux Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Janux Therapeutics has a P/E ratio of -15.4x.
See valuation multiples for Janux Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.4B | XXX | $1.4B | XXX | XXX | XXX |
| EV (current) | $416M | XXX | $416M | XXX | XXX | XXX |
| EV/Revenue | 62.2x | XXX | 39.3x | XXX | XXX | XXX |
| EV/EBITDA | -3.6x | XXX | -4.3x | XXX | XXX | XXX |
| EV/EBIT | -3.4x | XXX | -4.2x | XXX | XXX | XXX |
| EV/Gross Profit | 62.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | -15.4x | XXX | -20.4x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -9.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialJanux Therapeutics's last 12 month revenue growth is -52%
Janux Therapeutics's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $1.4M for the same period.
Janux Therapeutics's rule of 40 is -931% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Janux Therapeutics's rule of X is -1882% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Janux Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -52% | XXX | -24% | XXX | XXX | XXX |
| EBITDA Margin | -1752% | XXX | -914% | XXX | XXX | XXX |
| EBITDA Growth | 32% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -931% | XXX | -966% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -1882% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 646% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 1034% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Janux Therapeutics acquired XXX companies to date.
Last acquisition by Janux Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Janux Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Janux Therapeutics founded? | Janux Therapeutics was founded in 2017. |
| Where is Janux Therapeutics headquartered? | Janux Therapeutics is headquartered in United States of America. |
| How many employees does Janux Therapeutics have? | As of today, Janux Therapeutics has 81 employees. |
| Who is the CEO of Janux Therapeutics? | Janux Therapeutics's CEO is Dr. David Campbell, PhD. |
| Is Janux Therapeutics publicy listed? | Yes, Janux Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Janux Therapeutics? | Janux Therapeutics trades under JANX ticker. |
| When did Janux Therapeutics go public? | Janux Therapeutics went public in 2021. |
| Who are competitors of Janux Therapeutics? | Similar companies to Janux Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Janux Therapeutics? | Janux Therapeutics's current market cap is $1.4B |
| What is the current revenue of Janux Therapeutics? | Janux Therapeutics's last 12 months revenue is $6.7M. |
| What is the current revenue growth of Janux Therapeutics? | Janux Therapeutics revenue growth (NTM/LTM) is -52%. |
| What is the current EV/Revenue multiple of Janux Therapeutics? | Current revenue multiple of Janux Therapeutics is 62.2x. |
| Is Janux Therapeutics profitable? | Yes, Janux Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Janux Therapeutics? | Janux Therapeutics's last 12 months EBITDA is -$117M. |
| What is Janux Therapeutics's EBITDA margin? | Janux Therapeutics's last 12 months EBITDA margin is -1752%. |
| What is the current EV/EBITDA multiple of Janux Therapeutics? | Current EBITDA multiple of Janux Therapeutics is -3.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
